Precise MRD
Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
- Developer
- Myriad Genetics
- Intended use
- Mrd
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue, Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- Precise MRD current commercial configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.